Canadian Allergy & Immunology Today

Updates on the Treatment and Management of Urticaria in 2025

2025-10-16T20:04:25+00:00

Chronic spontaneous urticaria (CSU) is increasingly recognized as a complex immune-mediated disorder, driven by interactions among T cells, mast cells, and inflammatory mediators. This paper summarizes the latest advances in urticaria treatment and management, incorporating new targeted therapies and evidence-based clinical guidelines.

Venom Immunotherapy in 2025: Practical Insights for Community Allergists

2025-10-16T20:05:36+00:00

Hymenoptera venom allergy (HVA), caused by stings from bees, wasps, hornets, and yellow jackets, is one of the most common identifiable causes of anaphylaxis in adults. While local reactions are common, systemic responses can be fatal. Venom immunotherapy (VIT) offers long-term protection and is often curative. Introduced in the 1920s, VIT remains the only disease-modifying treatment for HVA.

Pearls from the European Academy of Allergy and Clinical Immunology (EAACI) Congress, 2025

2025-10-16T20:06:39+00:00

The European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held in Glasgow, Scotland, United Kingdom from June 13 to 16, centred on the overarching theme of “Breaking boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future.” Indeed, this year’s theme emphasized the intersection of environmental health and allergic diseases. The vibrant congress featured several presentations on immunological diseases in both adult and pediatric populations, along with breakthroughs in clinical and translational domains. Key topics included asthma, allergy, chronic spontaneous urticaria, and current global challenges such as pollution and climate change. This report highlights several key studies, organized under three main themes: pediatric studies, biologics in combined airways disease, and biomarkers.